Trial · NCT04612725
Results by group91
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 91
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12 | Benralizumab 30 mg | -7.50 | 95% Confidence Interval -8.94 to -6.05 | units on a scale | |
| Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12 | Benralizumab 60 mg | -8.28 | 95% Confidence Interval -9.76 to -6.80 | units on a scale | |
| Least Square (LS) Mean Change From Baseline in Itch Severity Score Over 7 Days (ISS7) at Week 12 | Placebo | -6.49 | 95% Confidence Interval -8.24 to -4.74 | units on a scale | |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Benralizumab 30 mg | Week 12 | -14.48 | 95% Confidence Interval -17.58 to -11.38 | units on a scale |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Benralizumab 60 mg | Week 12 | -16.77 | 95% Confidence Interval -19.94 to -13.59 | units on a scale |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Placebo | Week 12 | -12.41 | 95% Confidence Interval -16.17 to -8.65 | units on a scale |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Benralizumab 30 mg | Week 24 | -17.99 | 95% Confidence Interval -21.29 to -14.68 | units on a scale |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Benralizumab 60 mg | Week 24 | -19.17 | 95% Confidence Interval -22.51 to -15.83 | units on a scale |
| LS Mean Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Weeks 12 and 24 | Placebo | Week 24 | -15.43 | 95% Confidence Interval -19.43 to -11.44 | units on a scale |
| LS Mean Change From Baseline in ISS7 at Week 24 | Benralizumab 30 mg | -9.19 | 95% Confidence Interval -10.77 to -7.61 | units on a scale | |
| LS Mean Change From Baseline in ISS7 at Week 24 | Benralizumab 60 mg | -9.33 | 95% Confidence Interval -10.93 to -7.73 | units on a scale | |
| LS Mean Change From Baseline in ISS7 at Week 24 | Placebo | -7.57 | 95% Confidence Interval -9.48 to -5.66 | units on a scale | |
| Percentage of Responders at Weeks 12 and 24 | Benralizumab 30 mg | Week 12 | 22.0 | percentage of participants | |
| Percentage of Responders at Weeks 12 and 24 | Benralizumab 60 mg | Week 12 | 21.4 | percentage of participants | |
| Percentage of Responders at Weeks 12 and 24 | Placebo | Week 12 | 10.0 | percentage of participants | |
| Percentage of Responders at Weeks 12 and 24 | Benralizumab 30 mg | Week 24 | 28.8 | percentage of participants | |
| Percentage of Responders at Weeks 12 and 24 | Benralizumab 60 mg | Week 24 | 37.5 | percentage of participants | |
| Percentage of Responders at Weeks 12 and 24 | Placebo | Week 24 | 27.5 | percentage of participants | |
| LS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24 | Benralizumab 30 mg | Week 12 | -7.03 | 95% Confidence Interval -8.84 to -5.22 | units on a scale |
| LS Mean Change From Baseline in Hives Severity Score Over 7 Days (HSS7) at Weeks 12 and 24 | Benralizumab 60 mg | Week 12 | -8.47 | 95% Confidence Interval -10.32 to -6.62 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04612725/results